Medicine and Dentistry
Chronic Kidney Disease
81%
Nephropathy
55%
Cardiovascular System
45%
Maturity Onset Diabetes of the Young
29%
Glomerular Filtration Rate
28%
Blood Pressure
27%
Placebo
26%
Dapagliflozin
25%
End Stage Renal Disease
24%
Diabetes
23%
Clinical Trial
22%
Creatinine
21%
Kidney Function
20%
Proteinuria
17%
Albuminuria
16%
Acute Kidney Injury
16%
Hemodialysis
14%
Renal Failure
14%
ACE Inhibitor
14%
Diabetes Mellitus
13%
Urinary System
12%
Pressure Control
11%
Renin Angiotensin Aldosterone System
11%
Systolic Blood Pressure
11%
Patient with Type 2 Diabetes
11%
Randomized Controlled Trial
11%
Linagliptin
11%
Renovascular Hypertension
10%
Adverse Outcome
10%
Diabetic Nephropathy
10%
Heart Failure
10%
Disease
9%
Cardiovascular Disease
9%
Hazard Ratio
8%
Nephrosclerosis
8%
Meta-Analysis
8%
Antihypertensive Agent
7%
Personalized Medicine
7%
Randomized Clinical Trial
7%
Drug Therapy
7%
Biological Marker
6%
Intervention Trial
6%
Post-Hoc Analysis
6%
Finerenone
6%
Anemia
6%
Disease Exacerbation
6%
Angiotensin Receptor Antagonist
6%
Renal Biopsy
5%
Calcium Channel Blocking Agent
5%
Body Mass Index
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Kidney Disease
61%
Non Insulin Dependent Diabetes Mellitus
52%
Placebo
38%
Dapagliflozin
36%
End Stage Renal Disease
34%
Hemodialysis
30%
Creatinine
29%
Albuminuria
23%
Diabetic Nephropathy
22%
Clinical Trial
19%
Adverse Outcome
16%
Recombinant Erythropoietin
16%
Acute Kidney Failure
15%
Renin
15%
Kidney Failure
13%
Anemia
13%
Randomized Controlled Trial
13%
Angiotensin
12%
Dipeptidyl Carboxypeptidase Inhibitor
11%
Diabetes Mellitus
11%
Proteinuria
10%
Heart Failure
10%
Aldosterone
9%
Atrasentan
9%
Linagliptin
9%
Hypotension
8%
Cardiovascular Disease
8%
Finerenone
8%
Antihypertensive Agent
7%
Randomized Clinical Trial
7%
Disease
7%
Biological Marker
7%
Adverse Event
7%
Losartan
6%
Nephrosclerosis
6%
Bardoxolone Methyl
6%
All Cause Mortality
6%
Hyperkalemia
6%
Sodium Glucose Cotransporter 2 Inhibitor
5%
Angiotensin Receptor Antagonist
5%
Disease Exacerbation
5%
Cardiovascular Risk
5%
Spironolactone
5%
Renovascular Hypertension
5%
Hemoglobin A1c
5%
Keyphrases
Chronic Kidney Disease
61%
Dapagliflozin
31%
Type 2 Diabetes Mellitus (T2DM)
25%
Placebo
19%
Hypertension
19%
Adverse Outcomes
15%
Kidney
13%
Type 2 Diabetic Patients
13%
End-stage Renal Disease
12%
Estimated Glomerular Filtration Rate
12%
Cardiovascular Outcomes
11%
Cardiovascular Events
11%
Kidney Disease
10%
Albuminuria
9%
Diabetic Nephropathy
9%
Hazard Ratio
9%
Kidney Disease Progression
9%
Albumin-to-creatinine Ratio
8%
Angiotensin-converting Enzyme Inhibitor (ACEi)
8%
Randomized Controlled Trial
8%
Kidney Outcomes
8%
Proteinuria
8%
Cardiovascular Mortality
8%
Blood Pressure
8%
Linagliptin
7%
Diabetic Kidney Disease
7%
Diabetes
7%
Clinical Trials
7%
Major Adverse Kidney Events
7%
Darbepoetin Alfa
6%
Finerenone
6%
Renal Insufficiency
6%
Acute Kidney Injury
6%
Kidney Failure
5%
Renal Events
5%
Nephropathy
5%
Confidence Interval
5%
Decline in Kidney Function
5%
Hypertensive
5%
Hemoglobin
5%
Dyslipidemia
5%
Renin-angiotensin System Inhibitors
5%
DAPA-CKD
5%
Hypertensive Nephrosclerosis
5%
African American
5%
